Get started

Buysignal

$QOMUSDT Shiba Predator0xa71d0588EAf47f12B13cF8eC750430d21DF04974 SHIBA FLIPPED DOGE NOW WE FLIP SHIBA You are the Team Yes, we are all QOM and we are all the team. For this to work, “a thousand flowers must blossom” and we all must do our part Just like Shiba, there are no team tokens If you want to do something then do it, if someone asks for a hand out you can tell them that Shiba never paid for a thing. Trust The Process Flipping Shiba will take Diamond Hands. Don’t be short-sighted with QOM, there is a long road ahead of us. HODL Ask not what QOM can do for you, ask what you can do for QOM QOM started this with a contract deploy and a group, but it is really up to you (QOM also) to see what you can add. Work for you meal, add what you can and tell your frens. This is an army. It is new and small, but that also means we have advantage.
QLong
by BADQOMOCAWGOWLD
SOLANAThis is how I interpreted SOL price action. After exactly 1 year Solana is trading back to its previous most reasonable levels (DEMAND ZONE). The amazing bull run that lasted more than 50 days was due to different times and different reasons, but mostly irrational "exuberance" (SOL was said to be the ETH KiLlEr, but come on, coexistance and multi-blockchain will be a key factor for the future of crypto). Even though I'm a long term HODLER for SOL, I believe most likely target (trade wise) will be that 80$ area. Trade safe :)
Long
by Idonottrade
1
Is $CAL ready to push higher?Notes: * Strong up trend * Great earnings * Breaking out of a ~13 month base with higher than average volume * Forming a bull flag Technicals: Sector: Consumer Cyclical - Footwear & Accessories Relative Strength vs. Sector: 2.2 Relative Strength vs. SP500: 3.32 U/D Ratio: 1.52 Base Depth: 56.68% Distance from breakout buy point: 2.22% Volume 45.81% above its 15 day avg. Trade Idea: * You can enter now as the price is just breaking out of the $27.92 resistance area * Or you can wait for a break above the bull flag * Or if you want a better entry you can look to enter around the 27.8 area * This stock usually has local tops when the price closes around 25.12% above its 50 EMA * Consider selling into strength if the price closes 24.92% to 25.32% (or higher) above its 50 EMA * The last closing price is 11.57% away from its 50 EMA * Historical resistance comes around 29.85 and above that around 33.6 * Be on the lookout around 29.85
NYSE:CALLong
by HaseebKhan_90
BOTTOM IS CLOSE ON BTC!!!In this video i am explaining where i think we are going to go from here and also i'm looking at the 4 hourly, daily, weekly and monthly chart, as well i am looking at inflation rate chart and DXY . This is my third video and i hope you'll like it. Also i'm sorry for my speaking mistakes, I'm trying to improve my english. I forgot to mention that 300 weekly ma is also at the bottom of my monthly channel and also i forgot to mention that i am still in my short position from the top of the range at 32400k. What do you think about my second third video and analysis ? Feel free to leave a comment. If you like my ideas please follow me and like because you can always find something interesting on my profile, i am new to Treadingview but i have 6 years expirience in trading. DON'T SELL YOUR CRYPTO BTC TO THE MOON!!!
BITSTAMP:BTCUSD
by Mladen94
8
$SIDU Next Target PT 11 and higher Long term PT 60 and higherSidus Space is a Teammate on NASA’s $3.5 Billion Exploration Extravehicular Activity Services Contract Sidus Space, Inc. (NASDAQ:SIDU), a Space-as-a-Service company focused on mission critical hardware manufacturing; multi-disciplinary engineering services; satellite design, production, launch planning, mission operations; and in-orbit support is proud to announce that it is part of the Collins Aerospace team which was awarded NASA's Exploration Extravehicular Activity (xEVAS) services contract. Sidus Space, Inc., a space-as-a-service company, engages in the design, manufacture, launch, and data collection of commercial satellite worldwide. Its services include satellite manufacturing; precision manufacturing, assembly, and test; low earth orbit microsatellite; payload integrations; launch and support services; space-based data services and analytics; precision computer numerical control machining and fabrication; Swiss screw machining; wire cable harness fabrication; 3D composite and metal printing; and satellite deployment and microgravity testing and research services, as well as services related to electrical and electronic assemblies. The company also offers hardware solutions consisting of an external flight test platform to develop, test, and fly experiments, as well as delivers hardware, materials, and advanced electronics on the international space station; and space station integrated kinetic launcher for orbital payload systems. It serves commercial space, aerospace, defense, underwater marine, and other commercial and government customers. The company was founded in 2014 and is headquartered in Merritt Island, Florida. Sidus Space, Inc. is a subsidiary of Craig Technical Consulting, Inc.
NASDAQ:SIDULong
by BADQOMOCAWGOWLD
$BKSY Next Target PTs 4-4.75 Long term PT 29 and higherBlackSky Technologies Inc. (NYSE: BKSY) was awarded a basic order agreement from the Joint Artificial Intelligence Center (JAIC) to create and optimize data sets for use in DoD AI models and applications. The JAIC agreement has a ceiling value of $241 million over five years. BlackSky Technology Inc. provides geospatial intelligence, imagery and related data analytic products and services, and mission systems that include the development, integration, and operations of satellite and ground systems to commercial and government customers worldwide. The company processes a range of observations from its constellation, as well as various space, internet-of-things, and terrestrial based sensors and data feeds. Its products are used in government defense and intelligence; commercial, construction, and industrial; and catastrophe, climate, and environment applications. The company was incorporated in 2014 and is headquartered in Herndon, Virginia.
NYSE:BKSYLong
by BADQOMOCAWGOWLD
AUDCAD: Reversal Zones 🔄Price has trapped sellers with the false breakout of the head and shoulders. Since we have already swept a strong area of support to the left, I believe price may want to react at one of these major demands for buyers. I have my alerts set and will take a buy trade with the team IF criteria is met. Traders, if you have your own opinion about this idea, write in the comments section, I always reply. 💬 -------------------------------------------------------------------------------------------------------- Please like, subscribe, and share this idea with others! ⬇️ --------------------------------------------------------------------------------------------------------
Long
by AlkalineFX
34
$MREO Next Target PTs 2.50-4.50 and higher^ Key Words: I'm kicking us off with my pick, which is Mereo Biopharma. Now the stock was actually popping today on an article in "The Times" that says AstraZeneca is putting in a bid for the company. As you can see there, the stock up 73% there. And AstraZeneca also getting a slight boost as well. Now Mereo is a London-based US-listed company that specializes in therapies tied to cancer and orphan diseases. Now these are the diseases designated by the FDA as deadly, but so rare that they struggle commercially, so they receive special financial benefits for developing safe and effective drugs. Mereo's stock, though, down more than 70% over the past year. Now Mereo is a London-based US-listed company that specializes in therapies tied to cancer and orphan diseases. Now these are the diseases designated by the FDA as deadly, but so rare that they struggle commercially, so they receive special financial benefits for developing safe and effective drugs. Mereo's stock, though, down more than 70% over the past year. Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumor. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), a novel antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 antitrypsin deficiency. The company has a collaboration with The University of Texas MD Anderson Cancer Center to evaluate anti-TIGIT therapeutic antibody candidate, etigilimab. Mereo BioPharma Group plc was incorporated in 2015 and is based in London, the United Kingdom.
NASDAQ:MREOLong
by BADQOMOCAWGOWLD
$RYTM Next Target PTs 5.50-6.50 and higherRhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The company's lead product candidate is IMCIVREE, a potent melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is also developing setmelanotide, which is in Phase II clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, Smith-Magenis syndrome obesity, POMC epigenetic disorders, and other MC4R disorders. Rhythm Pharmaceuticals, Inc. has a collaborative research agreement with the Clinical Registry Investigating Bardet-Biedl Syndrome. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
NASDAQ:RYTMLong
by BADQOMOCAWGOWLD